Literature DB >> 19682599

Use of non-invasive bioluminescent imaging to assess mycobacterial dissemination in mice, treatment with bactericidal drugs and protective immunity.

Frank Heuts1, Berit Carow, Hans Wigzell, Martin E Rottenberg.   

Abstract

Monitoring the spread of mycobacterium in vivo using biophotonic imaging provides a fast, reliable and sensitive method to evaluate the distribution of the infection. Moreover, this technique allows for a significant reduction in the number of animals required in comparison to conventional anatomopathological studies. Here, we describe for the first time and validate the use of a luciferase-tagged recombinant Mycobacterium bovis BCG for non-invasive bioluminescent imaging of 1) bacterial dissemination in tissues, 2) the efficacy of treatment with anti-mycobacterial drugs and 3) the role of adaptive immune responses in controlling mycobacterial infection in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19682599     DOI: 10.1016/j.micinf.2009.08.005

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  19 in total

Review 1.  Noninvasive biophotonic imaging for studies of infectious disease.

Authors:  Nuria Andreu; Andrea Zelmer; Siouxsie Wiles
Journal:  FEMS Microbiol Rev       Date:  2010-10-19       Impact factor: 16.408

2.  Imaging tuberculosis with endogenous beta-lactamase reporter enzyme fluorescence in live mice.

Authors:  Ying Kong; Hequan Yao; Hongjun Ren; Selvakumar Subbian; Suat L G Cirillo; James C Sacchettini; Jianghong Rao; Jeffrey D Cirillo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

3.  Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.

Authors:  Tianyu Zhang; Si-Yang Li; Paul J Converse; Deepak V Almeida; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

4.  Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis.

Authors:  Anthony Vocat; Ruben C Hartkoorn; Benoit Lechartier; Ming Zhang; Neeraj Dhar; Stewart T Cole; Claudia Sala
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

5.  Reporter enzyme fluorescence (REF) imaging and quantification of tuberculosis in live animals.

Authors:  Ying Kong; Jeffrey D Cirillo
Journal:  Virulence       Date:  2010-11-01       Impact factor: 5.882

6.  Role for Gr-1+ cells in the control of high-dose Mycobacterium bovis recombinant BCG.

Authors:  Michael W Panas; Norman L Letvin
Journal:  Clin Vaccine Immunol       Date:  2014-06-11

7.  Simple and rapid method to determine antimycobacterial potency of compounds by using autoluminescent Mycobacterium tuberculosis.

Authors:  Sreevalli Sharma; Ekaterina Gelman; Chandan Narayan; Deepa Bhattacharjee; Vijayashree Achar; Vaishali Humnabadkar; V Balasubramanian; Vasanthi Ramachandran; Neeraj Dhar; Neela Dinesh
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

8.  Optimisation of bioluminescent reporters for use with mycobacteria.

Authors:  Nuria Andreu; Andrea Zelmer; Taryn Fletcher; Paul T Elkington; Theresa H Ward; Jorge Ripoll; Tanya Parish; Gregory J Bancroft; Ulrich Schaible; Brian D Robertson; Siouxsie Wiles
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

9.  Mycobacterium bovis-BCG vaccination induces specific pulmonary transcriptome biosignatures in mice.

Authors:  Elihu Aranday Cortes; Daryan Kaveh; Javier Nunez-Garcia; Philip J Hogarth; H Martin Vordermeier
Journal:  PLoS One       Date:  2010-06-28       Impact factor: 3.240

10.  Intravital excitation increases detection sensitivity for pulmonary tuberculosis by whole-body imaging with β-lactamase reporter enzyme fluorescence.

Authors:  Fatemeh Nooshabadi; Hee-Jeong Yang; Yunfeng Cheng; Madeleine S Durkee; Hexin Xie; Jianghong Rao; Jeffrey D Cirillo; Kristen C Maitland
Journal:  J Biophotonics       Date:  2016-10-18       Impact factor: 3.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.